Valuation: ValiRx plc

Market Cap 1.85M 2.47M 2.22M 2.02M 3.48M 232M 3.59M 24.41M 9.73M 124M 9.27M 9.07M 391M P/E 2024
-0.53x
P/E 2025 -0.62x
Enterprise Value 1.06M 1.41M 1.27M 1.16M 1.99M 133M 2.06M 13.97M 5.57M 70.93M 5.31M 5.19M 224M EV / Sales 2024
27,264,249x
EV / Sales 2025 54,121,446x
Free-Float
99%
Yield 2024 *
-
Yield 2025 -
1 day-7.14%
1 week-23.53%
Current month-23.53%
1 month-3.70%
3 months-18.75%
6 months-50.94%
Current year-61.19%
1 week 0.13
Extreme 0.13
0.18
1 month 0.12
Extreme 0.12
0.21
Current year 0.12
Extreme 0.12
0.48
1 year 0.12
Extreme 0.12
0.48
3 years 0.12
Extreme 0.12
13.5
5 years 0.12
Extreme 0.12
44.5
10 years 0.12
Extreme 0.12
968.75
Manager TitleAgeSince
Chief Executive Officer 55 2024-08-11
Director of Finance/CFO 81 -
Chief Tech/Sci/R&D Officer - 2025-03-26
Director TitleAgeSince
Director/Board Member 81 2006-08-31
Chairman 60 2024-07-24
Director/Board Member 55 2024-08-11
Date Insider Type Main position Quantity % Market Cap. Importance
3/4/26 Buy

Chief Executive Officer

1,000,000 0.1346%
10/18/22 Free

Director

75,000 0.0832%
10/18/22 Free

Director

75,000 0.0832%
Change 5-day change 1-year change 3-year change Capi.($)
-7.14%-23.53%-44.68%-98.92% 2.47M
-4.83%+3.51%+55.00%+62.02% 66.7B
+3.68%+7.91%+13.53%+83.71% 56.88B
-0.27%+2.96%+24.98%+96.76% 56.53B
+5.09%+9.89%+27.19%+103.27% 46.49B
+2.62%+1.68%+29.16%+36.08% 44.8B
+8.24%+0.51%+215.16%+807.84% 41.59B
-1.86%+10.13%+28.14%+53.61% 35.35B
+3.15%-1.68%+93.87%+65.65% 33.29B
+5.19%+1.62%-39.69%+381.71% 25.1B
Average +1.38%+0.62%+40.26%+159.17% 40.67B
Weighted average by Cap. +1.80%+3.07%+50.38%+167.29%

Financials

2024 2025
Net sales 0.05 0.07 0.06 0.05 0.09 6.25 0.1 0.66 0.26 3.34 0.25 0.24 10.53 0.03 0.04 0.04 0.03 0.06 3.94 0.06 0.41 0.17 2.1 0.16 0.15 6.64
Net income -1.92M -2.56M -2.3M -2.1M -3.61M -241M -3.72M -25.3M -10.09M -128M -9.61M -9.4M -405M -2.23M -2.98M -2.68M -2.45M -4.21M -280M -4.34M -29.47M -11.75M -150M -11.2M -10.96M -472M
Net Debt -1.54M -2.06M -1.85M -1.69M -2.91M -194M -3M -20.39M -8.13M -104M -7.75M -7.58M -327M -790K -1.06M -947K -866K -1.49M -99.27M -1.54M -10.43M -4.16M -52.97M -3.96M -3.88M -167M
Projected Income Statement - Annual - ValiRx plc
Logo ValiRx plc
ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.
Employees
11
Date Price Change Volume
26-11-09 GBX 0.1300 -7.14% 3,375,484
26-11-06 GBX 0.1400 -3.45% 5,473,161
26-11-05 GBX 0.1450 -9.38% 29,093,904
26-11-04 GBX 0.1600 -5.88% 6,449,059
26-11-03 GBX 0.1700 0.00% 1,297,396

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - ValiRx plc